NeuroMetrix (NASDAQ:NURO) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research report sent to investors on Tuesday morning. The firm issued a sell rating on the medical device company’s stock.

NeuroMetrix Trading Up 0.7 %

Shares of NURO stock opened at $4.40 on Tuesday. NeuroMetrix has a 1 year low of $2.66 and a 1 year high of $4.73. The firm has a market capitalization of $9.03 million, a P/E ratio of -0.96 and a beta of 2.15. The firm’s fifty day moving average price is $4.21 and its two-hundred day moving average price is $4.07.

Hedge Funds Weigh In On NeuroMetrix

A hedge fund recently bought a new stake in NeuroMetrix stock. Renaissance Technologies LLC acquired a new position in shares of NeuroMetrix, Inc. (NASDAQ:NURO) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 11,560 shares of the medical device company’s stock, valued at approximately $46,000. Renaissance Technologies LLC owned 0.57% of NeuroMetrix at the end of the most recent reporting period. 19.40% of the stock is owned by institutional investors and hedge funds.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.